153 - Buy One Get One Free: Learning All about the Dual Acting GIP and GLP-1 Receptor Agonist
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
Sean P. Kane, PharmD, BCPS
5 • 644 Ratings
🗓️ 6 September 2022
⏱️ 50 minutes
🧾️ Download transcript
Summary
In this episode, we will discuss mechanism, pharmacokinetics, efficacy, safety, and possible place in therapy for tirzepatide (Mounjaro), a new treatment for type 2 diabetes.
Key Concepts
- Tirzepatide is a novel GIP and GLP-1 receptor agonist resulting in glucose-dependent secretion of insulin and a decrease in glucagon secretion.
- This medication was FDA approved in May 2022 for the treatment of type 2 diabetes as an adjunct to diet and exercise. It is available as a long-acting once weekly pen injection to be administered subcutaneously.
- Current efficacy data exist from a 40-week trial which showed that tirzepatide was superior to semaglutide in A1c reduction and weight loss.
- The most common adverse effects of tirzepatide include GI concerns such as nausea, vomiting, and diarrhea as well as hypoglycemia.
References
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- Mounjaro. Package insert. Elli Lilly and Company. 2022.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions. |
| 0:11.0 | This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy. |
| 0:17.0 | This podcast contains general information for educational purposes only. This is not |
| 0:22.0 | professional advice and should not be used in lieu of obtaining advice from a qualified |
| 0:26.0 | health care provider. And now on to the show. Welcome to Helix Talk episode 153. I'm |
| 0:34.3 | your co-host, Dr. Kane. And I'm Dr. Patel. And in this episode number 153, we are going to discuss about a new drug molecule. The title of our episode is, |
| 0:45.9 | buy one, get one free, learning all about the dual acting GIP and GLP1 receptor agonist. So all things tears up a tide, its mechanism, pharmacokinetics, efficacy, |
| 0:58.0 | and safety data for one of its main trials and possible place in therapy, although guidelines |
| 1:04.8 | are kind of still behind and making any statements regarding this novel agent. |
| 1:08.2 | Dr. Patel, at least on the inpatient side, diabetes management is fairly straightforward. |
| 1:13.6 | We just give subcutaneous insulin or maybe even IV insulin. |
| 1:16.6 | But I know on the outpatient side, it's much more complicated than that with a variety of different |
| 1:21.6 | drugs and drug classes that pharmacy students need to learn in order to take great care of those patients with diabetes. |
| 1:27.8 | So can tell us a little bit more about kind of the landscape of diabetes meds in general |
| 1:32.3 | and where her Zepotide might fit into that? |
| 1:35.3 | Right. And you know, you're absolutely right. The landscape is a little bit more complicated. |
| 1:40.5 | In the recent year, ADA has done a great job delineating what therapies to choose |
| 1:48.1 | after that primary therapy of metformin based on, quote-unquote, compelling indications, |
| 1:54.6 | such as, you know, kidney disease, or if the patient has risk factors for ASCBD, or presence |
| 2:00.4 | of ASCBD, just to name a few. |
| 2:02.6 | And with the availability of other agents, such as the SGLD2i's, NDP4s, and GLP1 receptor agonist, |
| 2:11.6 | in addition to our traditional agents like metformin, sulfonyureas, diazolin and diomes, and obviously insulin, it's kind of getting |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Sean P. Kane, PharmD, BCPS, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Sean P. Kane, PharmD, BCPS and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.